Skip to Content
77 Mass Ave

New antibodies in just months

A faster way to develop immune-stimulating drugs has yielded a potential treatment for yellow fever and holds promise for covid-19.
August 18, 2020
antibodies conceptual illustration
Ben Barry

Yellow fever, a mosquito-borne hemorrhagic disease that is common in South America and sub-Saharan Africa, annually infects about 200,000 people and causes an estimated 30,000 deaths. While there is a vaccine, side effects make it inappropriate for some people, and there are no approved treatments for the disease.

Now an international team of researchers led by Professor Ram Sasisekharan may have developed one, using an innovative and unusually efficient approach. Their drug, an engineered monoclonal antibody, has shown success in early-stage clinical trials in Singapore.

Monoclonal antibodies are lab-­produced molecules that mimic the function of human antibodies in targeting foreign proteins for attack by the immune system. They hold promise for treating a variety of infectious diseases, but it usually takes several years to develop and test them. The MIT-led researchers demonstrated that they could design, produce, and begin clinical trials of their antibody drug within nine months.

“Traditional drug development processes are very linear, and they take many years,” Sasisekharan says. “If you’re going to get something to humans fast, you can’t do it linearly, because then the best-case scenario for testing in humans is a year to 18 months.”

Sasisekharan’s group was able to compress the antibody development timeline by performing many of the necessary steps in parallel, using analytical techniques to address regulatory risks associated with drug safety, manufacturing, and clinical study design.

The parallel process could also be used to develop new treatments for covid-19, says Sasisekharan, a professor of biological engineering. A covid-19 antibody treatment developed in just four months using this approach is now being tested in a clinical trial in Singapore.

“The mindset in the industry is that it’s like a relay race. You don’t start the next lap until you finish the previous lap,” Sasisekharan says. “In our case, we start each runner as soon as we can.”

Because there is a vaccine available for yellow fever, the researchers were able to perform a type of clinical trial known as a challenge test. They vaccinated volunteers and then, 24 hours later, gave them either the experimental antibody drug or a placebo. Two days after that, they measured whether the drug cleared the weakened viruses that make up the vaccine. After treatment, the virus was undetectable in blood samples from people who received the antibodies. The results were published in the New England Journal of Medicine in July.

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.